Savara(US:SVRA) Globenewswireยท2025-09-12 20:01Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Group 1: Allegations and Company Performance - The complaint alleges that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), specifically that it lacked sufficient details on chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - Following the announcement of a refusal to file (RTF) letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [3]. Group 2: Legal Proceedings and Participation - Shareholders may be eligible to participate in the class action against Savara Inc., with the option to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].